COVID-19 News & Media

News and Information on COVID-19

Labcorp Extends COVID-19 Genomic Sequencing Work With The CDC

 

Contract Extension Builds on Efforts to Pinpoint Mutations, Transmission Changes

 

BURLINGTON, N.C., June 30, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the extension of its work with the U.S. Centers for Disease Control and Prevention (CDC) to help identify and monitor variants of SARS-CoV-2, the virus that causes COVID-19. 


With the renewal of its contract, the company will continue providing genomic sequencing of random, de-identified samples that test positive for SARS-CoV-2. Labcorp’s sequencing efforts—first announced in January 2021—and the resulting data support the CDC’s goal of conducting a large-scale, longitudinal genomic survey of the virus in the United States.


Labcorp has supplied key information used to create a clearer state-level and nationwide picture of the virus, as well as changes in transmission and the spread of new variants. The sequencing data provided by the company to the CDC is combined with the results of similar endeavors by national, state, academic and private labs.


“When fighting a pandemic, the more data you have on the underlying virus and its variants, the better,” said Dr. Marcia Eisenberg, chief scientific officer at Labcorp Diagnostics. “We are proud to be a part of the data collection and analysis process and look forward to furthering this important work with the CDC.” 


Labcorp’s COVID-19 sequencing work builds on the company’s recent collaboration with the CDC to better understand SARS-CoV-2 and its impact on the U.S. population. This includes participation in projects aimed at pinpointing a marker for past infection, studying geographic and age-specific pathogen levels, as well as immune response.

 

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
 

Labcorp Contacts:                    
Media: Christopher Allman-Bradshaw — 336-436-8263 
[email protected]

Investors: Chas Cook — 336-436-5076                
[email protected] 

 

Scroll back to top of page